{"product_id":"staa-vrio-analysis","title":"STAAR Surgical Company (STAA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs STAAR Surgical Company (STAA) truly positioned for sustainable success? Our rigorous VRIO analysis cuts straight to the core, examining whether its resources are Valuable, Rare, Inimitable, and Organized to capture a lasting competitive edge. Discover the definitive verdict on STAAR Surgical Company (STAA)'s strategic strengths and weaknesses immediately below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 1. Proprietary Collamer Material Technology\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of STAAR Surgical Company’s moat, and frankly, it’s the reason the stock has commanded the premium it has. The Collamer material isn't just a component; it’s the entire value proposition for the EVO ICL line. This technology allows for a lens that is soft, highly biocompatible, and stable inside the eye, which directly translates to clinical preference and pricing power. For instance, the company reported a gross margin of \u003cstrong\u003e82.2%\u003c\/strong\u003e in the third quarter of 2025, which is exceptionally high for a medical device, showing how effectively they monetize this unique material.\u003c\/p\u003e\n\n\u003ch\u003eValue: Premium Pricing and Clinical Efficacy\u003c\/h\u003e\n\u003cp\u003eThe Collamer material is what makes the EVO ICL a premium offering in refractive surgery. Its unique properties - being soft and highly compatible with the eye’s environment - drive strong clinical outcomes that surgeons rely on. This clinical proof point allows STAAR Surgical Company to command pricing that competitors using standard acrylics simply cannot match. This value creation is evident in their financial performance; the reported gross margin of \u003cstrong\u003e82.2%\u003c\/strong\u003e in Q3 2025 is a direct reflection of this premium positioning. That margin is the bottom-line proof of concept.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Exclusive Material Science\u003c\/h\u003e\n\u003cp\u003eYes, this is rare. Collamer is proprietary, meaning no one else can legally use this specific hydrogel-collagen copolymer in an implantable lens. Competitors are stuck developing alternatives against a product that already has years of clinical validation. To be fair, other companies have their own proprietary materials, but STAAR Surgical Company owns the specific formulation and application for this category of phakic IOLs. This exclusivity is a significant differentiator in the market right now.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High Barrier to Entry\u003c\/h\u003e\n\u003cp\u003eImitating this is difficult, bordering on impossible in the near term. It’s not just about mixing chemicals; it requires deep, specialized material science expertise built over decades, plus proprietary, tightly controlled manufacturing processes. Reverse-engineering this would take a competitor years of dedicated R\u0026amp;D and significant capital expenditure just to get to a comparable starting point. What this estimate hides is the regulatory hurdle; even if they cracked the material science, gaining the necessary FDA and international approvals would add years to the timeline.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Centralized Focus\u003c\/h\u003e\n\u003cp\u003eThe organization is definitely structured around this asset. STAAR Surgical Company’s entire product development pipeline, R\u0026amp;D budget allocation, and marketing narrative are centered on leveraging the Collamer material and the EVO platform. Their operational readiness, including the expansion of manufacturing in Switzerland mentioned in Q1 2025 updates, shows a commitment to scaling production to meet the demand driven by this core technology. The company is organized to extract maximum value from this unique resource.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this core asset:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Reasoning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnabled \u003cstrong\u003e82.2%\u003c\/strong\u003e Gross Margin in Q3 2025; supports premium pricing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eProprietary Collamer material, used exclusively by STAAR Surgical Company.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires deep, long-term material science expertise and proprietary manufacturing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D and product strategy are entirely centered on leveraging the EVO ICL platform.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eMeets all four criteria, creating a strong, long-term barrier to entry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eGiven the sustained advantage, your immediate focus should be on maximizing the market penetration that this technology allows. The path forward is clear:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExpand surgeon training globally.\u003c\/li\u003e\n\u003cli\u003eAggressively market clinical superiority.\u003c\/li\u003e\n\u003cli\u003eEnsure supply chain keeps pace.\u003c\/li\u003e\n\u003cli\u003eDefend intellectual property vigorously.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStrategy: Maintain high production quality to protect the \u003cstrong\u003e82.2%\u003c\/strong\u003e margin potential.\u003c\/p\u003e\n\u003cp\u003eFinance: Draft a 13-week cash flow forecast incorporating projected capital needs for the Switzerland manufacturing scale-up by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 2. Global Market Leadership in Phakic IOLs\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Dominant player status in the specialized phakic IOL segment, supported by significant revenue generation and high international penetration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High global market share in the niche phakic IOL segment, though competitors are present.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; established brand recognition and surgeon training network present barriers, but competitor entry is possible.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes; sales execution and global footprint support the leadership position.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\u003cp\u003eThe company's leadership in the phakic IOL market is quantified by several key metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSTAAR Surgical Company secured the top position as the dominant player in the worldwide phakic IOL market in 2022.\u003c\/li\u003e\n\u003cli\u003eThe global phakic intraocular lens market was valued at approximately $\\$209$ million in 2022.\u003c\/li\u003e\n\u003cli\u003eThe company's share of the global implantable lens market reached $\\sim \\mathbf{15\\%}$ by the end of 2023.\u003c\/li\u003e\n\u003cli\u003eEstimated global phakic IOL segment share for STAAR in 2024 to 2025 is $\\mathbf{14\\%}$ to $\\mathbf{18\\%}$.\u003c\/li\u003e\n\u003cli\u003eIn fiscal year 2024, approximately $\\mathbf{94\\%}$ of the company's global revenue originated from sales outside the United States.\u003c\/li\u003e\n\u003cli\u003eFiscal year 2024 net sales outlook was projected to be between $\\$335$ million and $\\$340$ million.\u003c\/li\u003e\n\u003cli\u003eNet sales for the third quarter of 2025 were reported as $\\$94.7$ million.\u003c\/li\u003e\n\u003cli\u003eICL sales outside China for fiscal year 2024 reached $\\$151.6$ million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecific regional successes further illustrate market leadership:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn Japan, STAAR Surgical increased its market share from $8\\%$ in 2018 to $\\mathbf{73\\%}$ in 2023.\u003c\/li\u003e\n\u003cli\u003eBelgium and the Netherlands joined China and Japan as markets with a $\\mathbf{20\\%+}$ share of refractive industry procedures in 2024.\u003c\/li\u003e\n\u003cli\u003eSpain, a large European market, was approaching a $\\mathbf{20\\%}$ market share as of Q1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe VRIO assessment elements, supported by financial and statistical data, are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Assessment Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGlobal revenue of $\\$94.7$ million in Q3 2025. $\\sim \\mathbf{94\\%}$ of FY 2024 revenue from international markets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDominant player status in the phakic IOL market in 2022. Market share of $\\mathbf{73\\%}$ in Japan (2023).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRequires significant investment in surgeon education; $\\mathbf{1,200+}$ professionals trained in EVO ICL procedures in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReiterated FY 2024 net sales outlook of $\\$335$ million to $\\$340$ million. Cash, cash equivalents and investments available for sale totaled $\\$192.7$ million at the end of Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 3. Established Long-Term Clinical Track Record\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The established clinical track record is underpinned by the sale of over \u003cstrong\u003e3,000,000\u003c\/strong\u003e Implantable Collamer Lenses (ICLs) globally, with marketing presence in over \u003cstrong\u003e75\u003c\/strong\u003e countries. This extensive real-world usage generates unparalleled safety and efficacy data, which is critical for driving surgeon adoption and patient confidence in a premium vision correction procedure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The volume of over \u003cstrong\u003e3,000,000\u003c\/strong\u003e units sold, combined with a history of dedication to ophthalmic surgery for over \u003cstrong\u003e40 years\u003c\/strong\u003e, establishes a rare depth of post-market experience for a specific phakic intraocular lens technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Replicating this duration of clinical history, which includes post-market surveillance spanning decades, presents significant hurdles in terms of time investment and navigating complex regulatory pathways required for generating comparable outcome data.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The clinical data is systematically leveraged within organizational structures to enhance surgeon proficiency and market penetration. For example, STAAR University, launched in April \u003cstrong\u003e2024\u003c\/strong\u003e, provides surgeons access to key clinical outcomes data. Furthermore, the company trained over \u003cstrong\u003e1,200\u003c\/strong\u003e healthcare professionals in EVO ICL procedures in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\u003cp\u003eSupporting metrics related to the clinical track record:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal ICLs Sold (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e3,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGlobal sales milestone achieved.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Market Reach\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e75\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eGeographic distribution of product marketing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Reported Outcome\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e99.4%\u003c\/strong\u003e of patients surveyed would have the EVO ICL procedure again\u003c\/td\u003e\n\u003ctd\u003eIndication of high patient satisfaction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon Training (2024)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e1,200\u003c\/strong\u003e healthcare professionals trained\u003c\/td\u003e\n\u003ctd\u003eMeasure of organizational utilization of clinical data for adoption.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Focus Duration\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e40 years\u003c\/strong\u003e dedicated to ophthalmic surgery\u003c\/td\u003e\n\u003ctd\u003eIndicates the length of time supporting the clinical track record.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe clinical evidence supports the premium positioning of the EVO ICL:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe lens is designed to correct myopia, astigmatism, and presbyopia.\u003c\/li\u003e\n\u003cli\u003eThe procedure is minimally invasive, taking approximately \u003cstrong\u003e20 to 30 minutes\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe lens is biocompatible and does not require the removal of corneal tissue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 4. Strong, Debt-Free Balance Sheet\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides maximum financial flexibility for R\u0026amp;D, market expansion, and weathering macroeconomic volatility, evidenced by zero outstanding debt and \u003cstrong\u003e$192.7 million\u003c\/strong\u003e in cash\/investments at the end of Q3 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003cth\u003eAs of Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$192.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 26, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Outstanding Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 26, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$456.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$353.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, a debt-free status in the med-tech space, especially while investing heavily, is uncommon.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy to imitate with strong cash flow generation or a major equity raise, but the current state is a result of past discipline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes; the company is actively using this strength for a share repurchase program.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShare repurchase program announced: \u003cstrong\u003e$30 million\u003c\/strong\u003e in May 2025.\u003c\/li\u003e\n\u003cli\u003eShares repurchased during Q3 2025: approximately \u003cstrong\u003e115,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal cost for Q3 2025 repurchases: \u003cstrong\u003e$2.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage purchase price in Q3 2025: \u003cstrong\u003e$17.20\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eRemaining authorization under the program: \u003cstrong\u003e$23.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 5. Dual-Site, Geographically Diversified Manufacturing Base\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Mitigates single-point-of-failure risk (like earthquakes in California or geopolitical issues) by operating key facilities in both the US and Switzerland.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eLocation\/Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Primary Site)\u003c\/td\u003e\n\u003ctd\u003ePrincipal ICL Manufacturing Facility\u003c\/td\u003e\n\u003ctd\u003eMonrovia, California\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Diversification)\u003c\/td\u003e\n\u003ctd\u003eICL Manufacturing Site Expansion\u003c\/td\u003e\n\u003ctd\u003eNidau, Switzerland\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (Global Scale)\u003c\/td\u003e\n\u003ctd\u003eFY 2023 Worldwide Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$322.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (Geographic Reach)\u003c\/td\u003e\n\u003ctd\u003eFY 2023 Revenue Outside US\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (Investment Signal)\u003c\/td\u003e\n\u003ctd\u003ePP\u0026amp;E Investment Driver\u003c\/td\u003e\n\u003ctd\u003ePrimarily due to investments in manufacturing facilities in \u003cstrong\u003e2023\u003c\/strong\u003e and \u003cstrong\u003e2022\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Resilience Investment)\u003c\/td\u003e\n\u003ctd\u003eFY 2024 Gross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e76.3%\u003c\/strong\u003e (vs. \u003cstrong\u003e78.4%\u003c\/strong\u003e in FY 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many competitors rely on single-site manufacturing, but having a high-quality, established second site is not common.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSTAAR operates its principal manufacturing facility in \u003cstrong\u003eMonrovia, California\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSTAAR Surgical AG maintains manufacturing capabilities at its facility in \u003cstrong\u003eNidau, Switzerland\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRaw material for Collamer lenses is manufactured in \u003cstrong\u003eAliso Viejo, California\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eICL sales accounted for \u003cstrong\u003e99%\u003c\/strong\u003e of total sales in fiscal 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult; establishing a second, validated, high-precision medical device manufacturing site is capital-intensive and time-consuming.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company ended fiscal year 2023 with cash, cash equivalents, and investments available for sale of \u003cstrong\u003e$232 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes; the company has made recent investments to bolster the Swiss site for resilience.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe company is expanding manufacturing capabilities at the \u003cstrong\u003eNidau, Switzerland\u003c\/strong\u003e facility to mitigate risks associated with reliance on Southern California.\u003c\/li\u003e\n\u003cli\u003eGross profit margin for fiscal year 2024 was negatively impacted by period costs associated with the expansion of the \u003cstrong\u003eNidau, Switzerland\u003c\/strong\u003e facility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 6. EVO ICL Product Portfolio \u0026amp; Regulatory Approvals\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEVO Viva lens targets 1.7 billion people globally with presbyopia.\u003c\/li\u003e\n\u003cli\u003eBroader potential market includes 2.7 billion people with myopia.\u003c\/li\u003e\n\u003cli\u003eImmediate target market estimated at 5.2 million surgical procedures in 2025.\u003c\/li\u003e\n\u003cli\u003eEVO ICL sales reached $89.1 million in Q3 2024, up 10% year-over-year.\u003c\/li\u003e\n\u003cli\u003eQ1 2024 preliminary U.S. ICL sales reached a record $5 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003eEVO ICL Platform (Current)\u003c\/th\u003e\n\u003cth\u003eHistorical\/Competitor Phakic IOLs (e.g., Verisyse)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS FDA Approval Date (Phakic IOL)\u003c\/td\u003e\n\u003ctd\u003eMarch 2022 (EVO ICL)\u003c\/td\u003e\n\u003ctd\u003eSeptember 2004 (Verisyse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresbyopia Indication (CE Mark)\u003c\/td\u003e\n\u003ctd\u003eYes (EVO Viva, July 2020)\u003c\/td\u003e\n\u003ctd\u003eData Not Found\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLens Type\/Location\u003c\/td\u003e\n\u003ctd\u003ePosterior Chamber (ICL)\u003c\/td\u003e\n\u003ctd\u003eAnterior Chamber (Verisyse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Market Exclusivity (Posterior Chamber)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOnly\u003c\/strong\u003e phakic posterior chamber lens approved by the FDA\u003c\/td\u003e\n\u003ctd\u003eData Not Found\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEVO Viva received CE Mark approval in July 2020.\u003c\/li\u003e\n\u003cli\u003eGlobal ICL sales increased 18% for fiscal year 2023.\u003c\/li\u003e\n\u003cli\u003eICL unit growth outpaced refractive industry growth by at least 25 points in 2023.\u003c\/li\u003e\n\u003cli\u003eWillingness to recommend and satisfaction with product quality\/outcomes exceed 95% (November 2023 survey).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFiscal year 2023 gross profit margin was 78.4% of total net sales.\u003c\/li\u003e\n\u003cli\u003eFiscal year 2024 net sales outlook is $335 million to $340 million.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and investments available for sale were approximately $248 million as of March 29, 2024.\u003c\/li\u003e\n\u003cli\u003eGlobal market share of the implantable lens market increased from 5% (2018) to 15% (end of 2023).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2023 global ICL sales growth was 18%.\u003c\/li\u003e\n\u003cli\u003eQ4 2023 global ICL sales growth was 22%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 7. Global Commercial and Distribution Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Access to over 75 countries allows for revenue diversification, which helped offset inventory headwinds experienced in China in early 2025. More than \u003cstrong\u003e3,000,000\u003c\/strong\u003e ICLs have been sold to date globally.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries of Market Access\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e75\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICLs Sold (Aggregate)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e3,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from International Markets (FY 2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e94%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL Sales in China (FY 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$161.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL Sales Growth (Excluding China, FY 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13%\u003c\/strong\u003e to \u003cstrong\u003e$151.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; global reach is common, but a deep, established network specifically for a niche refractive procedure is less so. Direct distribution is maintained in key markets such as Japan, the U.S., Germany, Spain, Singapore, Canada, and the U.K.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; building out international distribution channels, especially in regulated markets, is a slow, relationship-based process.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Yes; the company is focused on making its complete product line available in existing markets. Recent regional performance highlights the network's strength:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAmericas Up \u003cstrong\u003e14%\u003c\/strong\u003e (Q3 2024 vs prior year)\u003c\/li\u003e\n\u003cli\u003eEMEA Up \u003cstrong\u003e12%\u003c\/strong\u003e (Q3 2024 vs prior year)\u003c\/li\u003e\n\u003cli\u003eAPAC Up \u003cstrong\u003e9%\u003c\/strong\u003e (Q3 2024 vs prior year)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 8. Dedicated Surgeon Education and Training Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Infrastructure like STAAR University and the EVO Experience Center directly drives surgeon confidence, leading to higher procedure adoption rates and market penetration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes; while training exists everywhere, a dedicated, centralized university\/center hub for a single product line is rare in this sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can build similar training centers, but they lack the proprietary clinical data to back it up initially.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes; this is a stated key focus for \u003cstrong\u003e2025\u003c\/strong\u003e strategic imperatives.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\u003cp\u003eKey metrics supporting the infrastructure's impact:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal ICLs Sold Worldwide\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e3,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMarch 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Surgeons Certified to Perform EVO ICL\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e700\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of September 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Professionals Trained in EVO ICL Procedures\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e1,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. EVO ICL Unit Growth (Proxy for Procedures)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst Half of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe commitment to education is formalized through specific initiatives and milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSTAAR University launched in \u003cstrong\u003eApril 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNew EVO Experience Center opened at headquarters in \u003cstrong\u003eSeptember 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Experience Center features immersive wet lab training stations for up to \u003cstrong\u003e24\u003c\/strong\u003e practitioners and lecture seating for \u003cstrong\u003e59\u003c\/strong\u003e individuals.\u003c\/li\u003e\n\u003cli\u003eThe center includes a \u003cstrong\u003e120-inch 4K\u003c\/strong\u003e video array for remote live surgery streaming.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTAAR Surgical Company (STAA) - VRIO Analysis: 9. High Gross Profitability Profile\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A gross margin consistently near or above 80% indicates strong pricing power and efficient cost of goods sold relative to the premium nature of the product.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Margin for Q3 2025 was \u003cstrong\u003e82.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Margin for Q2 2025 was \u003cstrong\u003e74.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Margin for Q1 2025 was \u003cstrong\u003e65.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrior Year Q3 Gross Margin was \u003cstrong\u003e77.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, for a company of this scale in the medical device space, such high margins are rare.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires both proprietary technology (Collamer) and optimized manufacturing scale.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes; the company is focused on cost controls to maintain this leverage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal operating expenses for Q3 2025 were $59.4 million, compared to $62.8 million in the prior year quarter.\u003c\/li\u003e\n\u003cli\u003eCost reductions were implemented in the first quarter of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\n\u003cp\u003eFinance: 13-week cash flow view incorporating the Q3 $192.7 million cash balance by Friday (as of September 26, 2025, for the ending balance):\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (USD Millions)\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Investments (Ending Balance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$192.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (Sep 26, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Sales\u003c\/td\u003e\n\u003ctd\u003e$94.7\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e82.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Income\u003c\/td\u003e\n\u003ctd\u003e$18.5\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e$8.9\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare Repurchases\u003c\/td\u003e\n\u003ctd\u003e$2.0\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516257296533,"sku":"staa-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/staa-vrio-analysis.png?v=1740217679","url":"https:\/\/dcf-model.com\/es\/products\/staa-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}